



## Malignant Adrenal Tumors – from Bench to Bedside

Guest Editors:

**Dr. Richard A. Feelders**

Department of Internal Medicine,  
Division of Endocrinology,  
Erasmus Medical Center, Dr.  
Molewaterplein 40, 3015 GD  
Rotterdam, The Netherlands

**Dr. Michiel N. Kerstens**

Department of Endocrinology,  
University Medical Center  
Groningen, Hanzeplein 1, 9713  
GZ Groningen, The Netherlands

Deadline for manuscript  
submissions:

**closed (1 August 2021)**

### Message from the Guest Editors

Dear colleagues,

Malignant adrenal tumors continue to present a challenge in many different ways. As a result of their low incidence, diagnostic delay is always lurking and expertise in the management of malignant adrenal tumors is usually not widely available. Adding to the complexity, malignant adrenal tumors have different origins (i.e. adrenal cortex, adrenal medulla, metastasis of extra-adrenal malignancy) and are highly heterogeneous in their clinical presentation and biological behavior. Radiological and pathological differentiation of malignant from benign adrenal tumors can be very difficult. In addition, there is an unmet need for new medical treatment modalities. In recent years, however, both basic and clinical research have produced much relevant and exciting new information on these disorders. The improved understanding of malignant adrenal tumors has either translated into changes in the clinical management or has revealed new characteristics or pathways which may ultimately provide novel diagnostic techniques or therapeutic options.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Samuel C. Mok

Department of Gynecologic  
Oncology and Reproductive  
Medicine, The University of Texas  
MD Anderson Cancer Center,  
Houston, TX 77030, USA

## Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

**Journal Rank:** JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

## Contact Us

---

*Cancers* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/cancers](http://mdpi.com/journal/cancers)  
[cancers@mdpi.com](mailto:cancers@mdpi.com)  
[X@Cancers\\_MDPI](https://twitter.com/Cancers_MDPI)